What Escitalopram Aurobindo Treats: Main Uses and Benefits

Escitalopram Aurobindo is applied across domains where additional symptomatic support is needed for symptoms related to mood and anxiety. The medication is used in situations involving certain distressing symptoms across conditions such as Major Depressive Episodes, Generalized Anxiety Disorder, Panic Disorder (with or without agoraphobia), Social Anxiety Disorder, and Obsessive-Compulsive Disorder.

---

The medication is relevant in conditions characterized by periods of heightened symptoms of Major Depressive Disorder, including persistent low mood and a noticeable loss of interest. It is also applied across therapeutic domains for persistent anxiety and panic episodes. It supports patients during episodes of heightened discomfort and assists with maintaining functional stability, which helps improve day-to-day comfort.

Quick Fact: Support for Symptom Manifestations

Symptom Domain	Description
Mood	Supports the patient in coping with persistent low mood and symptoms that create noticeable physiological strain.
Anxiety	Supports the patient in coping with excessive worry and constant tension.
Episodic Symptoms	Relevant for easing the distress associated with panic attacks and intrusive thoughts.

This information summarizes the official population eligibility and non-eligibility for escitalopram, based strictly on government regulatory documents.

Populations Who Must Not Use Escitalopram (Contraindications)

Use is prohibited for patients with a known hypersensitivity to escitalopram, citalopram, or any components in the formulation. The medicine is also strictly contraindicated if the patient is currently taking a Monoamine Oxidase Inhibitor (MAOI), including linezolid and intravenous methylene blue, or if they have taken one within the last 14 days. Additionally, concomitant use with pimozide and in patients with known QT-interval prolongation or congenital long QT syndrome is prohibited.

---

Age-Related and Conditional Eligibility

The medicine is generally indicated for adults. For Major Depressive Disorder, use is established in adolescents 12 years of age and older. For Generalized Anxiety Disorder, use is established in patients 7 years and older (for certain formulations). Use is not recommended in the pediatric population due to a lack of long-term safety data concerning development. Caution and/or dosage adjustment are required for elderly patients and those with hepatic impairment or severe renal impairment. Special caution is also necessary for patients with a history of seizures or mania/hypomania, a risk of angle-closure glaucoma, or who are pregnant or breastfeeding.

Escitalopram Aurobindo Interactions with other medicines and products

This section outlines interaction information documented in official regulatory labeling.

Contraindicated Combinations and Timing Rules

The co-administration of this medicine with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the high risk of Serotonin Syndrome. This prohibition includes both psychiatric MAOIs and non-psychiatric agents such as Linezolid and intravenous Methylene Blue. A mandatory 14-day separation period must elapse between discontinuing an MAOI and initiating this medicine, and vice-versa. Co-administration with Pimozide is also formally contraindicated because of the documented electrophysiological risk of QT interval prolongation.

Pharmacodynamic and Pharmacokinetic Interactions

The official profile defines two key interaction mechanisms:

• Pharmacodynamic (PD) Risk: Concomitant use with other serotonergic medicines, including St. John’s Wort or Tramadol, increases the risk of Serotonin Syndrome. Additionally, co-administration with drugs that interfere with hemostasis, such as NSAIDs and Warfarin, increases the officially documented risk of abnormal bleeding.
• Pharmacokinetic (PK) Impact: Escitalopram is categorized as a modest inhibitor of the CYP2D6 enzyme. This results in a significant increase in the total exposure (AUC) of co-administered CYP2D6 substrates; for instance, the AUC of Desipramine formally increases by 100%.

Population Note: Caution is documented for use in patients with hepatic impairment, as official data indicates reduced oral clearance which may lead to altered drug exposure.

Escitalopram Aurobindo is a highly selective compound that modulates neurotransmission within pathways involving the serotonergic system.

Selective Serotonin Reuptake Inhibition (SSRI)

This domain involves the primary mechanism of action: selective inhibition of the serotonin transporter (SERT) protein on presynaptic neurons. By binding to the SERT, escitalopram blocks the reuptake of serotonin (5-HT) from the synaptic cleft back into the neuron. This mechanistic cascade results in an immediate increase in the concentration and duration of 5-HT activity in the synapse, which initiates an alteration in neurotransmitter signaling dynamics.

---

Serotonergic Pathway Modulation

The elevated levels of 5-HT in the synaptic cleft lead to sustained activation of postsynaptic 5-HT receptors. Over time, this sustained activity contributes to the desensitization of specific autoreceptors, which typically regulate 5-HT release, thereby facilitating pathway adjustments mediated by the serotonergic system. This physiological adjustment modifies the effects of increased mediator activity, influencing the activity profile of specific neural circuits.

Escitalopram Aurobindo is approved solely for oral administration, provided in tablet strengths up to 20 mg and as an oral solution. The medicine is administered once daily, either in the morning or evening, and may be taken with or without food, according to the convenience of the individual.

---

The standard use protocol begins with an adult starting dose of 10 mg once daily. If a dose adjustment is necessary, any increase to the maximum recommended daily dose of 20 mg should only occur after a minimum of one week of the initial dose.

Administration guidelines mandate lower dosage ceilings for specific patient populations. For instance, the maximum recommended daily dose for most older adults (over 65 years) and patients with hepatic impairment is limited to 10 mg. For patients with mild to moderate renal impairment, no dosage adjustment is typically required.

---

If a dose is missed, it should be taken as soon as remembered, unless it is close to the next scheduled time, in which case the missed dose should be skipped; a double dose must not be taken. Upon completion of the full course of therapy, gradual dose reduction (tapering) is recommended to conclude administration. The duration of treatment often includes a maintenance phase, and the need for continuing therapy should be subject to periodic re-evaluation.

Research evidence / Overview of studies for Escitalopram Aurobindo

Evidence for use in Major Depressive Disorder (MDD)

Research has examined Escitalopram Aurobindo and its related compound for its use in patients experiencing Major Depressive Disorder, a condition characterized by fluctuating or episodic manifestations. The types of studies used in research exploring how symptoms change over time include short-term clinical trials. These studies report how symptoms evolved in the observed populations, specifically focusing on outcomes related to systemic or functional imbalance. Short-term trials generally findings help contextualize how patients reported their experience and measured changes were observed in study populations compared to control groups. However, study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

Evidence for use in Generalized Anxiety Disorder (GAD)

Escitalopram Aurobindo was evaluated in studies for patients with Generalized Anxiety Disorder (GAD), which is a condition where symptoms may vary in intensity. The research mainly examined the medication's effect during episodes where symptoms become more noticeable, particularly focusing on patient-reported outcomes describing perceived discomfort. Studies applied in research contexts involving fluctuating or unstable symptoms report how symptoms evolved in the observed populations across defined time intervals. Research highlights changes measured during the study period in study populations compared to control groups. These findings contribute to the broader evidence landscape for GAD.

---

Long-term studies and follow-up

Research has also explored responses observed over defined time intervals that may be considered long-term studies, focusing on conditions involving periods of heightened symptoms. These trials contribute to understanding the durability of the observed responses in conditions associated with acute or disruptive episodes. The evidence derived from settings with varying symptom burdens contributes to understanding symptom patterns over time but follow-up durations were limited in many cases. Therefore, there is limited information for long-term outcomes that are not fully established, and research is ongoing.

What is still uncertain about Escitalopram Aurobindo

Clinical research provides valuable context by highlighting evidence gaps. One main area of uncertainty is the variability of individual response; findings describe group patterns, not personal outcomes, and it remains difficult to predict who may experience the most beneficial changes. Additionally, comparative evidence is lacking in certain areas, and for some specialized groups, the evidence is limited, and certainty remains low.

Key Studies & References Depression in adults: treatment and management - NICE Guideline NG222

Common questions about Escitalopram Aurobindo (FAQ)

---

Q: Can I drink alcohol while taking this medicine?

Official prescribing information advises caution regarding alcohol consumption while taking Escitalopram Aurobindo. Although controlled studies in healthy volunteers did not show the medication increased alcohol's effects on thinking or motor skills, combining them may still be associated with risks, as alcohol can worsen symptoms of depression or anxiety. Patients should discuss alcohol use with a healthcare provider, as official product information suggests caution in limiting or avoiding alcohol due to the potential for combined effects, such as increased drowsiness or impaired judgment.

Q: Does this medicine make you sleepy?

The official regulatory documents list both trouble sleeping (insomnia) and sleepiness (somnolence) as possible side effects reported in clinical trials. Antidepressants like Escitalopram Aurobindo affect brain chemistry, and individual responses can vary. Individuals who experience these effects should take caution when performing activities that require alertness, such as driving or operating heavy machinery, until they understand their personal response to the medication.

Q: Is this medicine safe for long-term use?

Escitalopram Aurobindo has been studied in clinical trials for its approved uses, including studies over extended periods. For its indicated conditions, the established safety profile from both short-term and long-term data—including post-marketing surveillance—generally confirms its safety when taken as prescribed. The safety profile for continued treatment is best evaluated by a prescribing healthcare provider.

Q: Is this medicine safe for women or children 17 and younger?

Official product labeling indicates that Escitalopram Aurobindo is not indicated for use in children under 12 years of age for major depressive disorder (MDD) or not indicated for use in children under 7 years of age for generalized anxiety disorder (GAD). For women, the medication is prescribed for MDD and GAD in adults. Any consideration of use in non-indicated populations, such as women or children/adolescents, must adhere to regulatory guidelines and be decided by a healthcare provider based on a clinical assessment of risks and benefits.

Q: How should I store this medicine?

The medication should be stored in the original packaging at room temperature, typically between 68 F to 77 F (20 C to 25 C). Product labeling specifies storing the tablets in a dry place, away from excessive heat and moisture, to help maintain the medication's intended quality.

Q: Can this medicine be taken with food?

Official product information states that Escitalopram Aurobindo can be taken with or without food. While the overall absorption of the medicine is generally not significantly affected by food, taking it with a heavy meal may cause a slight delay in when the full effect is experienced.

The storage and disposal of Escitalopram Aurobindo tablets must adhere strictly to regulatory requirements for safety and product stability.

Storage Requirements

Escitalopram must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with storage limits mandated to be below 30 C.

• Protection: Keep the product in its original container to maintain protection from light and moisture.
• Child Safety: It is a mandatory requirement to store the medication out of the sight and reach of children.

Disposal Instructions

Any unused or expired Escitalopram must be disposed of in accordance with local requirements. The product must not be thrown away via wastewater or household trash to prevent environmental contamination.